Cerebral ischemia causes cell swelling and breakdown of the blood-brain barrier (BBB). Cytotoxic edema results from energy failure, and vasogenic edema occurs when the blood vessels are damaged. Proteases and free radicals are the end result of a molecular injury cascade. Matrix metalloproteinases (MMPs) are a gene family of extracellular matrix-degrading enzymes that disrupt the BBB. Tight junction proteins (TJPs), occludin and claudin-5, which form the endothelial barrier, are vulnerable to attack by MMPs. Basal lamina proteins, such as fibronectin, laminin, and heparan sulfate, are also degraded by MMPs. Reperfusion injury leads to a biphasic opening of the BBB, with the early opening occurring several hours after the onset of reperfusion due to activation of the constitutive enzyme gelatinase A (MMP-2). This initial opening is transient and followed 24 to 48 hours later by more intense damage to the blood vessel, which is associated with the expression and activation of gelatinase B (MMP-9) and stromelysin-1 (MMP-3). Synthetic MMP inhibitors restore the early integrity of the BBB but are ineffective in the later opening. Because these inhibitors block MMPs involved in angiogenesis and neurogenesis, they also slow recovery. The challenge is to identify agents that will protect the BBB, blocking vasogenic edema without interfering with recovery.
ASOGENIC EDEMA, which occurs due to breakdown of the BBB in cerebral ischemia, is aggravated by reperfusion. 4, 13, 16, 37 It has been recognized that hemorrhagic transformation after ischemic infarction occurs more commonly with embolism than with thrombosis, presumably because of clot resolution through reperfusion. 9, 15 Increased interest in the mechanisms of BBB damage and vasogenic edema was generated by the introduction of clot lysis with rt-PA, which increased the risk of symptomatic intracerebral hemorrhage. 2, 36 The safety of rt-PA treatment was improved with agents that prevent the extravasation of the enzyme into the brain across a damaged BBB. Disruption of the BBB is a complex process that involves multiple layers of cell processes and proteins. Tight junction proteins between endothelial cells form the initial interface. Surrounding the endothelial cells is a basal lamina composed of extracellular matrix proteins. Embedded in the basal lamina is a macrophagelike pericyte that has smooth muscle properties. Finally, the foot processes of the astrocytes form the outer layer. This series of layers is referred to as the "BBB," or more recently as the "neurovascular unit."
Data from earlier studies have shown that enzymes are capable of proteolytically degrading the extracellular matrix around blood vessels; these enzymes include plasmin, chondroitinase, and collagenase. 26 We have shown that the injection of bacterial collagenase into the caudate region in the rat leads to extensive bleeding. 31 Pursuing that observation further, we showed that the intracerebral injection of purified mammalian Type IV collagenase, which had been isolated from metastatic melanoma cells, opened the BBB and caused localized bleeding around the vessel. The hemorrhages resembled "ball hemorrhages" similar to those seen in hemorrhagic transformation, suggesting that reperfusion injury may be due to a proteolytic attack. 30 This finding led to a series of studies focused on isolating the Type IV collagenases in injured brain, culminating in the revelation that ischemic injury caused an increase in two Type IV collagenases, gelatinase A (MMP-2) and gelatinase B (MMP-9), along with plasminogen activators. 32 Type IV collagenases are members of a larger MMP gene family of proteolytic enzymes that play a critical role in development as well as in pathological processes such Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia as metastasis of cancer, arthritic destruction of collagen in joints, rupture of atherosclerotic plaques in the heart and carotid artery, acute inflammation in multiple sclerosis, vasogenic edema in stroke, brain infections, and brain trauma. 39 In stroke, the MMPs as well as cytokines and free radicals are induced as part of an inflammatory response related to hypoxia. 28 The action of MMPs is regulated by four endogenous TIMPs. 7 In addition to their destructive role in stroke, MMPs and TIMPs are important in the recovery phase when they facilitate angiogenesis and neurogenesis. Because of the wide range of diseases that involve pathological changes in the MMPs, there is great interest in the development of synthetic inhibitors of MMPs that could be used in therapy. These endeavors have met with mixed success because of the complex roles that MMPs play not only in injury but also in normal healing processes.
Proteolysis of TJPs by MMPs
Interfaces between the systemic circulation and brain tissues preserve the internal milieu of the brain. 1 The BBB tightly regulates the brain fluid environment by controlling the transport of substances into and out of the brain. The junction proteins, which form the tight junctions between the endothelial cells, assemble in the clefts of the cerebral blood vessels to restrict transport across the BBB. Several TJPs have been isolated and cloned. Within the cerebral endothelial cells are zona occludin molecules anchored to the actin cytoskeleton. Claudins form the tight junctions between the endothelial cells. Occludin is another of the TJPs within the clefts between the endothelial cells. At the level of the endothelial cells, which are directly in contact with the systemic circulation, the TJPs form a seal that blocks the entry of large proteins and charged molecules. 10, 14 The TJPs, including claudins and occludin, are proteolytically degraded by the MMPs. 38 In a suture stroke model in spontaneously hypertensive rats, a 90-minute MCAO with 3 hours of reperfusion resulted in cleavage of TJPs by activated MMP-2. Degradation of the TJPs was blocked by a synthetic broad-spectrum MMP inhibitor.
Gelatinase A, or MMP-2, is a constitutively expressed MMP that is normally present in the brain in a latent form and can be detected in the cerebrospinal fluid. The mechanism of MMP-2 activation involves the formation at the cell surface of a trimolecular complex of pro-MMP-2, MT1-MMP, and TIMP-2.
33,34 Small amounts of TIMP-2 facilitate activation of MMP-2, whereas larger amounts inhibit activation. The MT1-MMP is activated by the intracellular proprotein convertase furin. 6 All components necessary to activate MMP-2 are either present or induced within 3 hours after the onset of reperfusion. In the rats exposed to 90 minutes of MCAO, there was transient BBB opening 3 hours after the initiation of reperfusion. Using confocal microscopy, we have observed fragmentation of the TJPs within 3 hours, which differed from the arrayed linear structures that seemed to be "ziplocked" together ( Fig. 1) .
Western blotting, which was done to confirm the disruption seen on confocal microscopy, showed cleavage of the two major TJPs: claudin-5 and occludin. This breakdown could be prevented by treatment with a broad-spectrum MMP inhibitor, which adds further support to a role for MMP-2 in TJP degradation (Fig. 2) . After its transient early opening, the BBB remained relatively intact until 24 to 48 hours later, when a more disruptive opening occurred. We observed that by 24 hours the TJPs had moved out of the vasculature into the adjacent astrocytes. We were unable to determine whether the TJPs were formed by the astrocytes or taken up by them after being degraded.
The restored integrity of the BBB after its early opening suggests that TJPs are initially maintained within the blood vessel clefts and would remain intact if the later, more damaging stage of injury could be blocked. At later times the inflammatory response leads to the induction of MMP-3 and MMP-9. Matrix metalloproteinases are secreted as latent enzymes that require activation. In particular, MMP-9 is activated in the extracellular space by other proteases and free radicals. Results of in vitro studies have suggested that MMP-3 activates MMP-9, but the mechanisms in vivo are less well understood. 21 
Role of MMP-3 in Neuroinflammation
We have studied the role of MMP-3 in a model of neuroinflammation involving the intracerebral injection of LPS. 12 The region around the injection site becomes inflamed and a small region of BBB damage is induced. We have shown that opening the BBB in this model involves the induction and activation of the proinflammatory enzymes MMP-3 and MMP-9. Using immunohistochemistry, we found that MMP-3 is colocalized to the pericytes and microglia (Fig. 3) . Neutrophils contain formed MMP-9 that is released in packets during inflammation. 24 We observed the neutrophils around the site of injection. Given that both MMP-9 and MMP-3 were in the vicinity of the blood vessels, there may have been an interaction between them.
We further explored the role of MMP-3 by using mice in which the MMP-3 gene had been knocked out. 20 Neutrophils around the site of injection were counted with unbiased stereological methods. The MMP-3 knockout mice had fewer neutrophils than the wild type, suggesting that the MMP-3 contributed to opening of the BBB either by directly attacking the basal lamina around the blood vessels or by activating MMP-9, which in turn attacked the extracellular matrix proteins (Fig. 4) . We found that MMP-3 affected the TJPs; the MMP-3 knockout mice had smaller losses of claudin-5 and occludin than did the wild type (Fig. 5) . Furthermore, we showed that MMP-3 attacked proteins in the basal lamina, such as laminin, given that the MMP-3 knockout mice had larger amounts of laminin than did the wild type (Fig. 6 ). Most likely, the MMP-3 directly attacked the laminin considering that it is a known substrate of the enzyme, although it is possible that other MMPs, such as MMP-9, contributed to the attack on the TJPs. Because they are also formed as latent enzymes, a mechanism for activation is needed.
When the inflammatory MMPs are present, they are free to move within the extracellular space, where they could create greater damage than those attached to the cell surfaces. Although the studies in the MMP-3 knockout mice were done using an inflammation model rather than an ischemic one, the mechanisms of damage to the BBB are probably similar between the two types of injuries and could explain the marked loss of TJPs from the cerebral endothelial cells seen at the time of the second opening of the BBB. The early opening was dominated by the MMP-2 bound to the cell surface by the MT1-MMP, which restricted damage to the vicinity of the cell surface in the immediate region. When the more generalized inflammatory response took place at 24 to 48 hours, there was a release of the unbound MMP-9 and MMP-3, and the damage caused by the unconstrained proteases in the extracellular space was more extensive.
Role of MMPs in rt-PA-Induced Intracerebral Bleeding
Treatment of stroke with rt-PA improves outcome. 2 Although the incidence of hemorrhagic transformation is similar in treated and untreated patients, there is a greater risk of symptomatic intracerebral hemorrhage, resulting in morbidity and death, in treated patients. 8 The reason for this phenomenon has been unraveled over the past several years. Normally there is an incidence of hemorrhagic transformation that is estimated to be as high as 60% in embolic stroke. 15 Reperfusion in itself has been recognized for more than 50 years as a major cause of bleeding in the brain. 9 The rt-PA in blood is prevented from entering the brain by the BBB. In the early stages of infarction, there is a transient opening of the BBB. When rt-PA is given by 3 hours after the onset of stroke, as is recommended, the BBB is compromised and rt-PA extravasates into the brain. Once in contact with brain cells, the rt-PA activates the MMPs, causing an attack on the BBB with hemorrhage. 19 Thus, the beneficial effect of rt-PA requires that it remain within the vessels.
Synthetic inhibitors of MMPs block the opening of the BBB. 29 Inhibitors have been developed to block the MMPs involved in the metastasis of cancer, and most of the clinical trials have been focused on cancer treatment. 5, 22 The most effective MMP inhibitors currently used are hydroxymate-based compounds.
11 Data in clinical trials have shown some benefit for their use in the treatment of advanced cancer, but side effects related to joint pain due to the loss of extracellular matrix remodeling have forced the closure of these trials. Given the role of the MMPs in the early opening of the BBB and in hemorrhage, it was reasoned that these agents would be useful in rt-PA treatment. An MMP inhibitor was tested in the multiple emboli model of stroke and was shown to reduce the number of hemorrhages. 17 Personnel at our laboratory have studied the effect of a broad-spectrum MMP inhibitor, BB-94, administered intraperitoneally in rats. 25 Animals with MCAO for various times underwent reperfusion. After 1.5 hours of occlusion and 16.5 hours of reperfusion, only 1 of 12 animals died, even when given 10 mg/kg of rt-PA, which is the dose used in rats (Fig. 7A) . After 6 hours of occlusion and 12 hours of reperfusion, however, death occurred in a significantly increased number of animals, that is, one of six animals without treatment and five of six with rt-PA treatment. When BB-94 was given shortly before treatment with rt-PA in animals that had undergone 6 hours of occlusion and 12 hours of reperfusion, the death rate was decreased significantly. The effect of reperfusion on the BBB was studied with 14 C-sucrose. After 6 hours of occlusion and 1 hour of reperfusion, the sucrose space (the ratio of sucrose in the brain to that in the blood) was greater than 7%. Treatment with BB-94 significantly reduced the opening (Fig. 7B ). This result indicates that the protection provided by the MMP inhibitor was most likely attributable to the prevention of opening the BBB and the inability of the rt-PA to enter the brain.
Matrix Metalloproteinase Inhibitors for Treatment of Vasogenic Brain Edema
The toxicity of rt-PA occurs when there is extravasation of rt-PA from the blood into the brain, where it activates glutamate receptors in neurons and increases the activity of the MMPs. 23, 35 The challenge is to identify the optimal MMP inhibitor and the appropriate time window for its use. Authors of several studies have identified MMP inhibitors as possible treatments for vasogenic edema. In an earlier study, we found that another broad-spectrum MMP inhibitor, BB-1101, was also effective. 29 Both of these
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Bar graph demonstrating results of stereological methods for neutrophil counts 24 hours after LPS or saline (SAL) injection into the caudate nucleus. Counts of myeloperoxidaseimmunoreactive neutrophils were greater in the LPS-injected caudate nucleus in both wild type (WT) and MMP-3 knockout (KO) mice. In the MMP-3 knockout mice, however, there were significantly fewer neutrophils in the caudate nucleus compared with those in the wild type mice, in both saline-and LPS-injected hemispheres. Four mice for each WT and KO group. *p Ͻ 0.01, **p Ͻ 0.001. (From Gurney et al., 2006.) agents are very poorly soluble, making it unlikely that they will be used in clinical trials.
Confounding the use of the MMP inhibitors is the fact that MMPs play an important role in the recovery phase and possibly in the normal turnover of extracellular matrix. In a recent study, the authors showed that MMPs are critical for recovery because they are involved in both angiogenesis and neurogenesis; MMP inhibitors slowed recovery after cerebral infarction. 18, 40 An antibody to MMP-9 has been shown to reduce the size of an infarct in a model of stroke in rats. 27 Genetically modified animals lacking the MMP-9 gene have less damage to the BBB and smaller strokes than wild-type animals. 3 These studies have been focused on the acute phase of stroke, and the long-term effects of these agents are unclear. We have used MR imaging to document early injury to the BBB noninvasively and to measure the size of the infarct at 48 hours. After the initial MR imaging studies, animals were tested behaviorally for 4 weeks. We found that treatment for 3 days with the broad-spectrum inhibitor BB-1101 dramatically reduced the initial BBB opening, had no effect on infarct size, and caused a slowing in recovery (Sood et al., unpublished data). The use of these agents for the early prevention of BBB opening must include long-term follow-up to identify a safe therapeutic window for their use. In addition, as more is learned about the MMPs involved in the recovery phase, selective MMP inhibitors can be developed and tested.
Future Studies
Many laboratories are now engaged in studies on the role of MMPs in damage to the BBB that results in vasogenic edema. Rational use of MMP inhibitors to protect from MMP-mediated proteolysis of TJPs in stroke treatment will require a better understanding of the mechanisms of the proteolysis of TJPs by MMPs. Synthetic inhibitors have shown promise in controlling damage to both the extracellular matrix proteins that comprise the basal lamina and the tight junctions. Which inhibitors will be useful clinically remains an open question. Newer ones are being developed that act selectively against one or more of the MMPs, sparing others; such inhibitors are important because the beneficial effects may be due to one FIG. 5 . Western gel blots and bar graphs showing the effect of LPS injection on TJPs in MMP-3 knockout and wildtype mice. Representative bands from one mouse are shown in the upper portion of each figure. The major forms of 23 kD claudin-5 and 66 kD occludin were measured using densitometry. A: Twenty-four hours after LPS or saline injection, it became apparent that the LPS injection resulted in a significant decrease in claudin-5 levels in both wild-type (WT) and MMP-3 knockout (KO) mice (three animals for each group, *p Ͻ 0.05). B: Measurements of occludin also decreased after LPS injection. However, claudin-5 and occludin levels decreased to a lesser extent in the MMP-3 knockout than in wild-type mice (*p Ͻ 0.05 and **p Ͻ 0.001). The lower bands on each Western blot are probably degradation products. GAPDH = glyceraldehyde-3-phosphate-dehydrogenase. (From Gurney et al., 2006.) group of enzymes, whereas others may cause the damaging effects. Studies are needed to define the timing of MMP inhibitor treatment so that the beneficial effects of the MMPs are not blocked. Research may require the short-term use of these agents in the early stages of stroke or reperfusion. With newer methods of developing and screening potential therapies and advances in the use of MR imaging to characterize tissue damage, it may be possible to reduce damage to the extracellular matrix and TJPs, which in turn would reduce the risk of vasogenic edema and hemorrhage in cerebral ischemia and expand the therapeutic window for the use of thrombolysis in stroke.
